我国区域生物医药产业分工研究  

Research on Division of Labor of Regional Biomedical Industry in China

作　　者：濮润[1] 董丽娟 唐尚锋 敖翼[1] 孙燕荣 PU Run;DONG Lijuan;TANG Shangfeng;AO Yi;SUN Yanrong(China Biotechnology Development Center,Beijing 100039,China;Shenyang Pharmaceutical University,Shenyang 110016,China;Huazhong University of Science and Technology,Wuhan 430074,China)

机构地区：[1]中国生物技术发展中心,北京100039 [2]沈阳药科大学,沈阳110016 [3]华中科技大学,武汉430074

出　　处：《医药导报》2019年第10期1376-1378,共3页Herald of Medicine

基　　金：国家社科基金-新时代我国生物医药产业分工与高质量发展研究(19CJY003)

摘　　要：从21世纪初开始,我国鼓励生物医药产业集群化发展,以全国各地的生物医药产业园区为代表,集聚效应渐显。现有研究主张在集群内按产业链、新药研发链进行分工,但缺少系统研究,且对不同集群间的产业链分工很少涉及。该文对我国区域产业分工及区域生物医药产业分工的研究现状进行综述。Since the beginning of this century, China has encouraged the cluster development of bio-pharmaceutical industry.Represented by biomedical industrial parks all over the country, the agglomeration effect is gradually evident. The existing research advocates that the labor shall be divided according to industry chain and new drug R&D chain in clusters, but lack of systematic research on the division of labor among different clusters.This paper was devoted to summarizing the research status of regional industrial division and regional biomedical industry division in China.

关 键 词：生物医药 区域 产业分工 集群 

分 类 号：R977[医药卫生—药品]